Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide in Severe Obesity and Established Cardiovascular Disease
NCT05882045Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2023
- Primary completion
- Apr 2026
- Modality
- Peptides, Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of retatrutide in obesity, sponsored by Eli Lilly and Company. Started May 2023; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05882045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05882045.